ClinicalTrials.gg

Program

PF-08103402

A development code.

In Pfizer's pipeline, undisclosed. Its studies are mostly in Asthma, led by Pfizer.

Furthest: phase 1, since Jun 16, 20261 company-led study, 1 open or runningNext primary completion: Mar 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Jun 16, 2026Jun 16, 2026Mar 30, 2027phase 1 · NCT07660731
  • Named in Pfizer’s own pipeline as PF-08103402, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2026First study: phase 1 study in AsthmaFirst studyNCT07660731 · 133 planned · United States, Belgium

Ahead

  1. Mar 30, 2027Primary completion: phase 1 study in AsthmaNCT07660731

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“undisclosed”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07660731Asthma · United States, Belgium1RecruitingMar 30, 2027133

How it is read

Names in the registry

  • “PF-08103402”, 1 entry

Codes read as this program: PF08103402.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.